Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
On June 11, 2020, Arcturus Therapeutics Holdings announced that CEO Joseph Payne will present at the Raymond James Human Health Innovation Conference, scheduled for June 15-18, 2020. The presentation is set for 3:00 pm Eastern Time on June 18. Arcturus, based in San Diego, focuses on developing messenger RNA therapeutics for rare diseases and vaccines. The company's innovative technologies include LUNAR® lipid-mediated delivery and STARR™ mRNA Technology. Arcturus has a diverse pipeline targeting conditions like Ornithine Transcarbamylase Deficiency and SARS-CoV-2.
Arcturus Therapeutics has commenced a Phase 1 study for ARCT-810, an mRNA-based therapeutic targeting Ornithine Transcarbamylase (OTC) deficiency. The first healthy volunteer has been dosed in this double-blind, placebo-controlled trial, assessing safety, tolerability, and pharmacokinetics. OTC deficiency, a serious urea cycle disorder affecting approximately 10,000 globally, currently lacks FDA-approved treatments. The ARCT-810 program, leveraging Arcturus’ LUNAR delivery platform, aims to express the OTC enzyme in liver cells, potentially preventing severe neurological damage.
Arcturus Therapeutics (Nasdaq: ARCT) announced promising preclinical data for its COVID-19 vaccine candidate, LUNAR-COV19, demonstrating robust adaptive immune responses. Key findings include a significant increase in CD8+ T-cells and a balanced Th1/Th2 response. The STARR™ mRNA technology elicited higher anti-spike protein antibodies compared to conventional mRNA across all doses, particularly at lower doses. With plans for human clinical trials set for summer 2020, the results indicate strong support for the vaccine's effectiveness and potential for clinical protection against COVID-19.
Arcturus Therapeutics Holdings Inc. announced significant progress in its COVID-19 STARR™ mRNA vaccine, LUNAR-COV19, showcasing robust preclinical immunogenicity with a single low dose. The company successfully raised $75.5 million through a secondary stock offering and maintains $59.5 million in cash, sufficient to sustain operations for over two years. The net loss for Q1 2020 was approximately $9.8 million, with revenues declining to $2.6 million compared to $4.3 million in Q1 2019. Clinical trials for the vaccine are set to begin this summer, with manufacturing support from Catalent.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will announce its financial results for Q1 2020 after market close on May 7, 2020. A conference call and webcast to discuss the results will be held at 4:30 PM ET on the same day. The company focuses on developing mRNA therapeutics for rare diseases and vaccines, with a robust pipeline that includes candidates for conditions such as Ornithine Transcarbamylase Deficiency, Cystic Fibrosis, and a self-replicating mRNA vaccine for SARS-CoV-2.
Summary not available.